NICE backs Bayer’s Nubeqa for prostate cancer
The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of German drugmaker Bayer’s (BAYN: DE) Nubeqa (darolutamide) in combination with ADT as an option for treating adult patients with mHSPC who are unsuitable for chemotherapy (docetaxel).
The decision means eligible prostate cancer patients with mHSPC will now have access to darolutamide plus ADT through the National Health Service (NHS) in England and Wales.
Today’s decision by the NICE follows the recent authorization of the indication in June by the Medicines and Healthcare products Regulatory Agency (MHRA) and is based on positive results from the pivotal Phase III ARANOTE trial, evaluating the efficacy and tolerability profile of darolutamide plus ADT in patients with mHSPC.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze